The role of surgery in the management of oesophageal cancer

Lancet Oncology

Volumn 4, Issue 8, 2003, Pages 481-488

  Wu, Peter C ^a   Posner, Mitchell C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; FLUOROURACIL; VINDESINE;

ADVANCED CANCER; ANESTHESIOLOGICAL TECHNIQUES; CANCER LOCALIZATION; CANCER STAGING; CLINICAL TRIAL; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HUMAN; IMAGING SYSTEM; INDIVIDUALIZATION; LYMPHADENECTOMY; MINIMALLY INVASIVE SURGERY; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SAFETY; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

EID: 0041475771     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01167-7     Document Type: Review

References (73)

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF, Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-89.
2. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
3. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26 (5 suppl 15): 2-8.
4. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
5. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-24.
6. DeMeester TR. Esophageal carcinoma: current controversies. Semin Surg Oncol 1997; 13: 217-33.
7. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
8. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130: 883-90.
9. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90: 150-55.
10. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995; 4: 85-92.
11. Whooley BP, Law S, Murthy SC, Alexandrou A, Wong J. Analysis of reduced death and complication rates after esophageal resection. Ann Surg 2001; 233: 338-44.
12. Karl RC, Schreiber R, Boulware D, Baker S, Coppola D. Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg 2000; 231: 635-43.
13. Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999; 230: 392-400; discussion 400-03.
14. Hagen JA, DeMeester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 2001; 234: 520-30; discussion 530-31.
15. Swanson SJ, Batirel HF, Bueno R, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg 2001; 72: 1918-24; discussion 1924-25.
16. Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg 2001; 234: 581-87.
17. Collard JM, Otte JB, Fiasse R, et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001; 234: 25-32.
18. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-27.
19. Weigel TL, Frumiento C, Gaumintz E. Endoluminal palliation for dysphagia secondary to esophageal carcinoma. Surg Clin North Am 2002; 82: 747-61.
20. Nash CL, Gerdes H. Methods of palliation of esophageal and gastric cancer. Surg Oncol Clin N Am 2002; 11: 459-83, xiii.
21. Sihvo EI, Pentikainen T, Luostarinen ME, et al. Inoperable adenocarcinoma of the oesophagogastric junction: a comparative clinical study of laser coagulation versus self-expanding metallic stents with special reference to cost analysis. Eur J Surg Oncol 2002; 28: 711-15.
22. Adler DG, Baron TH. Endoscopic palliation of malignant dysphagia. Mayo Clin Proc 2001; 76: 731-38.
23. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347: 1662-69.
24. Chu KM, Law SY, Fok M, Wong J. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg 1997; 174: 320-24.
25. Jacobi CA, Zieren HU, Muller JM, Pichlmaier H. Surgical therapy of esophageal carcinoma: the influence of surgical approach and esophageal resection on cardiopulmonary function. Eur J Cardiothorac Surg 1997; 11: 32-37.
26. Goldminc M, Maddern G, Le Prise E, et al. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993; 80: 367-70.
27. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001; 72: 306-13.
28. Rindani R, Martin CJ, Cox MR. Transhiatal versus Ivor-Lewis oesophagectomy: is there a difference? Aust N Z J Surg 1999; 69: 187-94.
29. Swisher SG, Deford L, Merriman KW, et al. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg 2000; 119: 1126-32.
30. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280: 1747-51.
31. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-37.
32. Lerut T. Esophageal surgery at the end of the millennium. J Thorac Cardiovasc Surg 1998; 116: 1-20.
33. Holscher AH, Bollschweiler E, Bumm R, et al. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery 1995; 118: 845-55.
34. Clark GW, Peters JH, Ireland AP, et al. Nodal metastasis and sites of recurrence after en bloc esophagectomy for adenocarcinoma. Ann Thorac Surg 1994; 58: 646-53; discussion 653-54.
35. Steup WH, De Leyn P, Deneffe G, et al. Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg 1996; 111: 85-94; discussion 94-95.
36. Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000; 232: 743-52.
37. Kitagawa Y, Fujii H, Mukai M, et al. Intraoperative lymphatic mapping and sentinel lymph node sampling in esophageal and gastric cancer. Surg Oncol Clin N Am 2002; 11: 293-304.
38. Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997; 337: 1188-94.
39. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220: 364-72; discussion 372-73.
40. Altorki NK, Skinner DB. Occult cervical nodal metastasis in esophageal cancer: preliminary results of three-field lymphadenectomy. J Thorac Cardiovasc Surg 1997; 113: 540-44.
41. Lerut T, Coosemans W, De Leyn P, et al. Reflections on three field lymphadenectomy in carcinoma of the esophagus and gastroesophageal junction. Hepatogastroenterology 1999; 46: 717-25.
42. Torres AJ, Sanchez-Pernaute A, Hernando F, et al. Two-field radical lymphadenectomy in the treatment of esophageal carcinoma. Dis Esophagus 1999; 12: 137-43.
43. Tabira Y, Okuma T, Kondo K, Kitamura N. Indications for three-field dissection followed by esophagectomy for advanced carcinoma of the thoracic esophagus. J Thorac Cardiovasc Surg 1999; 117: 239-45.
44. Nigro JJ, DeMeester SR, Hagen JA, et al. Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. J Thorac Cardiovasc Surg 1999; 117: 960-68.
45. Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002; 236: 177-83.
46. Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 1991; 48: 411-20.
47. Kato H, Watanabe H, Tachimori Y, Iizuka T. Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg 1991; 51: 931-35.
48. Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998; 175: 47-51.
49. Law SY, Wong J. Esophageal cancer surgery: the value of controlled clinical trials. Semin Surg Oncol 1997; 13: 281-87.
50. Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118: 670-77.
51. Waxman I, Saitoh Y, Raju GS, et al. High-frequency probe EUS-assisted endoscopic mucosal resection: a therapeutic strategy for submucosal tumors of the GI tract. Gastrointest Endosc 2002; 55: 44-49.
52. Posner MC, Alverdy J. Hand-assisted laparoscopic surgery for cancer. Cancer J 2002; 8: 144-53.
53. Swanstrom LL, Hansen P. Laparoscopic total esophagectomy. Arch Surg 1997; 132: 943-47; discussion 947-49.
54. Luketich JD, Schauer PR, Christie NA, et al. Minimally invasive esophagectomy. Ann Thorac Surg 2000; 70: 906-11; discussion 911-12.
55. Nguyen NT, Follette DM, Wolfe BM, et al. Comparison of minimally invasive esophagectomy with transthoracic and transhiatal esophagectomy. Arch Surg 2000; 135: 920-25.
56. Law S, Wong J. Use of minimally invasive oesophagectomy for cancer of the oesophagus. Lancet Oncol 2002; 3: 215-22.
57. Urba S. Combined modality therapy of esophageal cancer - standard of care? Surg Oncol Clin N Am 2002; 11: 377-86.
58. Arnott SJ, Duncan W, Kerr GR, et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol 1992; 24: 108-13.
59. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992; 16: 1104-09; discussion 1110.
60. Wang M, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int J Radiat Oncol Biol Phys 1989; 16: 325-27.
61. Gignoux M, Roussel A, Paillot B, et al. The value of preoperative radiotherapy in esophageal cancer: results of a study of the EORTC. World J Surg 1987; 11: 426-32.
62. Launois B, Delarue D, Campion JP, Kerbaol M. Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet 1981; 153: 690-92.
63. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-33.
64. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-84.
65. Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114: 210-17.
66. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 1992; 127: 1446-50.
67. Roth JA, Pass HI, Flanagan MM, et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988; 96: 242-48.
68. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-67.
69. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337: 161-67.
70. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-13.
71. Posner MC, Gooding WE, Lew JI, et al. Complete 5-year follow-up of a prospective phase II trial of preoperative chemoradiotherapy for esophageal cancer. Surgery 2001; 130: 620-26; discussion 626-28.
72. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-98.
73. Bedenne L, Michel P, Bouche O, et al. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol 2002; 19: